A new efficient chiral synthesis of enantiopure arimoclomol (2) is reported from 
(R)-(-)-glycidyl nosylate (11) with complete retention of chiral integrity. 
Off-target pharmacology of arimoclomol (2) was evaluated against a 
representative set of drug targets and showed modest binding to a few kinases. 
Pharmacokinetic data was generated in vivo in mouse and showed a low 
brain : plasma ratio. These studies will be helpful towards a better 
understanding of the PK-PD relationship of 2 in disease models.